Paradium AI outlines Q4 alpha launch of Tablation as updated content drives roughly 50% more page views (NYSE:PAAI)

Paradium.AI, Inc. (PAAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Paradium.AI Reports Q3 2026 Results Quarterly Performance Impacted by Continued Traffic Headwinds; Monetization and Technology Initiatives Gain Momentum, Boosting Yield and Content Output NEW YORK – November 9, 2026 – Paradium.AI, Inc., formerly known as The Arena Group Holdings,

Paradium.AI, Inc. (PAAI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Strategic Platform Agreement On September 14, 2026, Paradium. AI., Inc. (“Paradium” or the “Company”) entered into a ten-year Strategic Platform Agreement (the “Platform Agreement”) with RTB Digital, Inc. (“RTB,” and together with the Company, the “Parties

Roundtable (RTB) announced a 10-year, $1 billion deal with Paradium.AI (PAAI) to migrate PAAI's media portfolio onto RTB's AI/DeFi MediaOS. RTB expects $100 million annual revenue and EBITDA positivity, with 100 million monthly consumers. The partnership aims to reduce costs, increase profits, and provide global scale for media brands.

Raymond James reiterated an Outperform rating and $11 price target for Black Diamond Therapeutics (BDTX), citing positive Phase 2 trial data for silevertinib in non-small cell lung cancer. The stock is near its 52-week low of $1.60. The FDA has provided feedback on the Phase 3 trial design, and the company reported Q3 2026 earnings. Stifel raised its price target to $14, maintaining a Buy rating.

Goldman Sachs believes the semiconductor selloff has been excessive, highlighting Nvidia (NVDA), Broadcom (AVGO), and AMD (AMD) as attractive investment opportunities. The firm notes that these stocks are now in oversold territory, with compelling valuations even under pessimistic scenarios. The call comes after a significant market downturn, with the Philadelphia Semiconductor Index down 21% over the past month.

Regeneron Pharmaceuticals reported that its liver drug candidate reduced liver fat by up to 80% in early trials. The company cautioned that further studies are needed to confirm clinical benefits. Regeneron is exploring non-invasive measures for liver disease assessment and has identified genetic factors linked to lower liver disease risk. The company estimates the U.S. MASH market at $1 billion, potentially growing to $15 billion by 2035.